CRB 15
Alternative Names: CRB-15; Depletin; IL-15 cytokine receptor blocker; Interleukin-15 cytokine receptor blockerLatest Information Update: 02 Jul 2007
At a glance
- Originator Beth Israel Deaconess Medical Center; Cardion
- Developer Beth Israel Deaconess Medical Center; Cardion; Roche
- Class Antirheumatics
- Mechanism of Action Interleukin 15 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Crohn's disease; Multiple myeloma; Psoriasis; Rheumatoid arthritis; Transplant rejection
Most Recent Events
- 02 Jul 2007 Preclinical development is ongoing
- 06 Oct 2004 This compound is still in active development for Transplant rejection and Rheumatoid arthritis
- 06 Oct 2004 No development reported - Preclinical for Multiple myeloma in USA (unspecified route)